Leti Announces Launch of First European Nanomedicine Characterisation Laboratory

Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval

GRENOBLE, France – July 1, 2015 – CEA-Leti today announced the launch of the European Nano-Characterisation Laboratory (EU-NCL)funded by the European Union's Horizon 2020 research and innovation programm [1]e. Its main objective is to reach a level of international excellence in nanomedicine characterisation for medical indications like cancer, diabetes, inflammatory diseases or infections, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to regulatory agencies to get the approval for clinical trials and, later, marketing authorization.

"As reported in the ETPN White Paper [2], there is a lack of infrastructure to support nanotechnology-based innovation in healthcare," said Patrick Boisseau, head of business development in nanomedicine at CEA-Leti and chairman of the  European Technology Platform Nanomedicine (ETPN). "Nanocharacterisation is the first bottleneck encountered by companies developing nanotherapeutics. The EU-NCL project is of most importance for the nanomedicine community, as it will contribute to the competiveness of nanomedicine products and tools and facilitate regulation in Europe."

EU-NCL is partnered with the sole international reference facility, the Nanotechnology Characterization Lab of the National Cancer Institute in the U.S. (US-NCL) [3], to get faster international harmonization of analytical protocols.

"We are excited to be part of this cooperative arrangement between Europe and the U.S.," said Scott E. McNeil, director of U.S. NCL.  "We hope this collaboration will help standardize regulatory requirements for clinical evaluation and marketing of nanomedicines internationally. This venture holds great promise for using nanotechnologies to overcome cancer and other major diseases around the world."

EU-NCL is also closely connected to national medicine agencies and the European Medicines Agency to continuously adapt its analytical services to requests of regulators. EU-NCL is designed, organized and operated according to the highest EU regulatory and quality standards.

This project is important for Europe, as it will be the first transnational infrastructure in nano-medicine. It aims at fostering innovation by sharing knowledge and technologies between academia and industry.

The mission of EU-NCL is:

  • To provide a trans-disciplinary testing infrastructure covering a comprehensive set of preclinical characterisation assays (physical, chemical, in-vitro and in-vivo biological testing), allowing researchers to fully comprehend the biodistribution, metabolism, pharmacokinetics, safety profiles and immunological effects of their medicinal nano-products.
  • To foster the use and deployment of standard operating procedures (SOPs), benchmark materials and quality management for the preclinical characterisation of medicinal nano-products.
  • To promote intersectoral and interdisciplinary communication among key drivers of innovation, especially between developers and regulatory agencies.

This project, led by CEA-Tech (Leti and Liten, FR), brings together nine partners from eight countries:

  • Joint Research Centre - European Commission (IT)
  • European Research Services GmbH (DE),
  • Leidos Biomedical Research, Inc. (U.S.)
  • Trinity College Dublin (IE)
  • Stiftelsen SINTEF (NO)
  • University of Liverpool (UK)
  • EMPA (CH) and
  • Gesellschaft für Bioanalytik Münster (GE).

Within EU-NCL, six analytical facilities will offer transnational access to their existing analytical services for public and private developers, and will also develop new or improved analytical assays to keep EU-NCL at the cutting edge of nanomedicine characterisation.

EU-NCL is funded by the European Commission for a four-year period, with nearly 5 million euros allocated.

[1] This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 654190.

2 Nanomedicine 2020, contribution of Nanomedicine to Horizon 2020, ETPN, Nov 2013

http://ncl.cancer.gov/

About CEA-Leti  (France)

As one of three advanced-research institutes within the CEA Technological Research Division, CEA-Leti serves as a bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. It is committed to creating innovation and transferring it to industry. Backed by its portfolio of 2,800 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched 54 startups. Its 8,500m² of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. With a staff of more than 1,800, Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo. Follow us on  www.leti.fr and @CEA_Leti.

Press contacts

Agency
+33 6 74 93 23 47       
Email Contact

 



Read the complete story ...


Review Article Be the first to review this article
Aldec Webinar Nov 30

Featured Video
Editorial
Peggy AycinenaWhat Would Joe Do?
by Peggy Aycinena
Computer History Museum: the Future of War is Here
More Editorial  
Jobs
Senior PIC Test Development Engineer for Infinera Corp at Sunnyvale, CA
Senior SW Developer for EDA Careers at San Jose, CA
ASIC Design Engineer for Infinera Corp at Sunnyvale, CA
Principal PIC Hardware Controls Engineer for Infinera Corp at Sunnyvale, CA
REVISED***Director Product Line RF/IC for EDA Careers at San Jose, CA
Upcoming Events
“Empowering Leadership with WIT and WISDOM” at SEMI 673 South Milpitas Blvd. Milpitas CA - Nov 28, 2017
Artificial Intelligence and Convolution Neural Networks Discussion at San Jose State University Student Union Theater San Jose CA - Dec 4, 2017
Silicon Valley's Only Comprehensive Embedded Systems Conference at San Jose Convention Center 150 W. San Carlos St. San Jose CA - Dec 5 - 7, 2017
Oski Technology’s Decoding Formal Club Meeting at The Conference Center San Jose CA - Dec 7, 2017



Internet Business Systems © 2017 Internet Business Systems, Inc.
25 North 14th Steet, Suite 710, San Jose, CA 95112
+1 (408) 882-6554 — Contact Us, or visit our other sites:
AECCafe - Architectural Design and Engineering TechJobsCafe - Technical Jobs and Resumes GISCafe - Geographical Information Services  MCADCafe - Mechanical Design and Engineering ShareCG - Share Computer Graphic (CG) Animation, 3D Art and 3D Models
  Privacy PolicyAdvertise